Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBIT Margin (2018 - 2026)

Exagen filings provide 9 years of EBIT Margin readings, the most recent being 19.73% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 199.0% to 19.73% in Q1 2026 year-over-year; TTM through Mar 2026 was 20.65%, a 403.0% increase, with the full-year FY2025 number at 21.13%, up 337.0% from a year prior.
  • EBIT Margin hit 19.73% in Q1 2026 for Exagen, up from 29.91% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 15.29% in Q2 2025 to a low of 184.91% in Q2 2022.
  • Median EBIT Margin over the past 5 years was 34.77% (2023), compared with a mean of 48.66%.
  • Biggest five-year swings in EBIT Margin: crashed -13995bps in 2022 and later surged 15014bps in 2023.
  • Exagen's EBIT Margin stood at 112.88% in 2022, then skyrocketed by 67bps to 37.39% in 2023, then soared by 34bps to 24.77% in 2024, then fell by -21bps to 29.91% in 2025, then soared by 34bps to 19.73% in 2026.
  • The last three reported values for EBIT Margin were 19.73% (Q1 2026), 29.91% (Q4 2025), and 17.98% (Q3 2025) per Business Quant data.